Publications

Quarterly summary of recent safety communications

Prescriber Update 40(2): 40
June 2019

The table below is a summary of recent safety communications to healthcare professionals and consumers.

Date	Communication	Topic
16 May 2019	Monitoring	Risk of infections with Prolia (denosumab)
15 May 2019	Dear HealthCare Professional Letter	Actemra – New important identified risk: Hepatoxicity (PDF 361 KB, 3 pages)
7 May 2019	Monitoring	Review of the risks of harm and chance of benefit of Cafergot (ergotamine tartrate + caffeine) under section 36 of the Medicines Act 1981
24 April 2019	Alert	Take care when prescribing and dispensing levodopa-containing products (Madopar, Sinemet, Kinson)
23 April 2019	Alert	Consumer level recall – Baby teething powder and baby colic powder
16 April 2019	Alert	Hydrochlorothiazide: risk of non-melanoma skin cancer
11 April 2019	Monitoring	Breast implants and anaplastic large cell lymphoma
26 March 2019	Dear HealthCare Professional Letter	Darzalex – New important identified risk: Hepatitis B reactivation (PDF 103 KB, 2 pages)
22 March 2019	Alert	Consumer level recall – Normal saline, a component of The Trusts first aid kits
6 March 2019	Monitoring	Losartan approved medicines supplied in New Zealand not affected by recalls overseas
4 March 2019	Alert	Use of sodium valproate (Epilim) in girls and women – Change to indications and contraindications
15 February 2019	Dear Healthcare Professional Letter	Esmya – Important safety update following reports of serious liver injury (PDF 115 KB, 2 pages)
11 February 2019	Alert	Consumer level recall – Bronchi-cough pills (Qiguanyan Kesou Tanchuanwan)